Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
Sets
Sets
Favorites
Favorites
Log in
Log in
About
Pricing
Company Reports
Speciality European Pharma
Speciality European Pharma
Download report
Favorite
Financial
Marketed Drugs
Clinical Trials
Financial
Stock price
No data
Company Revenue
No data
Revenue by Drug
Marketed Drugs
Therapeutic Areas:
All
Classification:
All
Include Generics:
Trade Name
Drug Name
Approved
Patent Expires
Indication
Plenaxis
Abarelix
2003-11-25
—
Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Drug Name
Phase 1
Phase 2
Phase 3
Phase 4
Indication
Abarelix
prostatic neoplasms
,
endometriosis
Aglatimagene besadenovec
prostatic neoplasms
Nepidermin
rectal neoplasms
,
endometrial neoplasms
,
salivary gland neoplasms
,
endometrioid carcinoma
,
breast neoplasms
,
prostatic neoplasms
,
lung neoplasms
,
colorectal neoplasms
,
non-small-cell lung carcinoma
,
liver neoplasms
,
head and neck neoplasms
,
neoplasm metastasis
,
multiple myeloma
,
hypercholesterolemia
,
plasma cell neoplasms
,
neoplasms
,
stomach neoplasms
,
recurrence
,
squamous cell carcinoma
,
leukemia
,
pancreatic neoplasms
,
carcinoma
,
adenocarcinoma
,
osteoporosis
,
hepatocellular carcinoma
,
local neoplasm recurrence
,
huntington disease
,
multiple sclerosis
,
sclerosis
,
b-cell chronic lymphocytic leukemia
,
lymphoid leukemia
,
hyperlipoproteinemia type ii
,
myeloid leukemia acute
,
myeloid leukemia
,
asthma
,
liver diseases
,
digestive system diseases
,
thyroid neoplasms
,
thyroid diseases
,
tonsillitis
,
drug therapy
,
heart failure
,
postmenopausal osteoporosis
,
pneumonia
,
gaucher disease
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) |
Terms of Use